Orphan drug developers to discuss how to bring therapies to market faster

Though orphan drug designations have increased across established markets like US, Europe and Japan, high rates of clinical attrition as well as pricing & reimbursement issues remain problematic. Join over 600 industry and key stakeholders next April where these issues will be discussed and debated!

Join the 4th annual World Orphan Drug Congress USA, the largest global orphan drug conference! This will be held in Washington DC from April 23rd -25th, 2014.

Key speakers include Emil Kakkis, President and Founder of Ultragenyx, Congressman Leonard Lance, a Capitol Hill advocate of rare disease research, Christopher Austin, NIH's translation science division director, Roy Beveridge, Chief Medical Officer of private payer Humana, Bert Bruce, Pfizer's Rare Disease Unit Vice President for Commercial Operations and Betsy Garofalo, Novartis' recently appointed Head of Clinical Development Sciences.

This conference and expo provides a platform for key movers and shakers of the orphan drug industry to come together and discover partnerships and collaborations to expedite orphan drugs to patients globally.

Various facets to highlight key needs of the industry are as follows:

  • Hear inspiring keynote presentations from industry's key opinion leaders
  • Leverage from case studies across the entire process of orphan drug development at the Seminar Theater
  • Find bankable up and coming orphan drugs being developed by start-ups and scientist at the Pitch & Partner program
  • Evaluate, even purchase, the right product or service showcased at the Exhibit Area
  • Learn how to attract investment or how to best reach out to patient groups in-depth at the 3-hour pre-conference workshops
  • Meet over 50 patient groups at the Patient Zone in the Exhibit Area

Participants will learn:

  • How to successfully navigate new regulatory implementations like the breakthrough therapy designation
  • How to reassess the architecture and metrics of discovery, quantification and reimbursement of orphan drugs
  • How to ensure the market sustainability while maintaining orphan drugs' premium pricing
  • How to access emerging orphan drug markets like Brazil, China, Russia, Israel and MENA
  • How to launch and develop a successful patient registry

To register or learn more visit www.terrapinn.com/orphandrug